Protara Therapeutics, Inc. (TARA)
| Market Cap | 273.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.44M |
| Shares Out | 54.08M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 658,306 |
| Open | 5.01 |
| Previous Close | 4.99 |
| Day's Range | 4.96 - 5.19 |
| 52-Week Range | 2.77 - 7.82 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 23.60 (+366.4%) |
| Earnings Date | May 1, 2026 |
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price target is $23.6, which is an increase of 366.40% from the latest price.
News
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects ...
Protara Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
TARA-002 shows strong efficacy and safety in NMIBC, with six-month CR rates leading the field and a robust regulatory path for both BCG-unresponsive and BCG-naive populations. The pipeline includes a pivotal trial for lymphatic malformations and IV choline chloride, with multiple catalysts expected in 2024.
Protara Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
TARA-002 is advancing in late-stage trials for NMIBC and LM, with strong interim efficacy and safety data, and regulatory progress supporting broader market entry. IV Choline Chloride targets a large unmet need in parenteral nutrition, backed by patent protection through 2041.
Protara Therapeutics Transcript: Study update
Interim phase II results for TARA-002 in NMIBC show strong six- and twelve-month response rates in both BCG-unresponsive and BCG-naïve cohorts, with high reinduction success and a favorable safety profile. The therapy's ease of use and robust efficacy position it as a promising new option.
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2...
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of ca...
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Late-stage programs in bladder cancer and lymphatic malformations are advancing, with pivotal data and regulatory clarity expected by 2026. The company targets significant rare disease markets and anticipates annual FDA approvals from 2027 to 2030, supported by strong clinical efficacy and expedited pathways.
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA...
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Announces Closing of $75 Million Public Offering
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dis...
Protara Announces Pricing of $75 Million Public Offering
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dis...
Protara Announces Proposed Public Offering
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dis...
Protara Therapeutics Transcript: Study Update
Updated phase II data show TARA-002 achieved a 69% six-month and 50% 12-month CR rate in BCG-naive NMIBC, with strong durability and a favorable safety profile. FDA has agreed to a registrational trial using intravesical chemotherapy as comparator, targeting fewer than 500 patients.
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12...
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics Transcript: Study Update
Interim phase II results for TARA-002 in pediatric lymphatic malformations show high clinical success and a favorable safety profile, consistent with historical data from OK-432. The company plans to complete the study next year and engage the FDA for potential approval, targeting a significant unmet need in this rare disease.
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical success Clinical success achieved with one or two doses of TARA-002 in...
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 Expect to present interim analysis from approximately 25 six-month ev...
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...